Savient Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SVNTQ 0.0019
price chart
Bridgewater-based Savient Pharmaceuticals OKd for Chapter 11 plan
Savient Pharmaceuticals Inc., a developer of a treatment for gout before its business was sold, got approval of a liquidating Chapter 11 plan, with U.S.
Savient Pharmaceuticals Files for Bankruptcy
Savient Pharmaceuticals Inc., the developer of a treatment for gout, sought bankruptcy protection and court approval to sell its assets to a US WorldMeds LLC unit for $55 million, the company said.
Savient Pharmaceuticals files for Chapter 11 bankruptcy  Reuters
Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks To ...  PR Newswire (press release)
Related articles »  
Savient Pharma Sells to GTCR-Backed Crealta For $120M
Bridgewater, NJ-based Savient said today that it's reached a deal to sell itself to Crealta Pharmaceuticals, a recently-created specialty pharmaceutical company based in Lake Forest, IL. Crealta has agreed to pay $120.4 million to acquire Savient and ...
GTCR's Crealta To Buy Savient Pharmaceuticals  Wall Street Journal (blog)
Savient acquired by Crealta Pharmaceuticals in $120M bankruptcy auction  NJBIZ
Related articles »  
Savient Pharmaceuticals gets approval from US Bankruptcy Court to sell all ...
Savient Pharmaceuticals filed for bankruptcy in October. Citing a filing in the Bankruptcy Court in Wilmington, Delaware, Bloomberg reported that Savient had debts amounting to $260 million and only had assets of $74 million.
Savient Receives Approval From Bankruptcy Court To Sell Substantially All ...  PR Newswire (press release)
Bankrupt Savient Gets OK For $120M Sale To Crealta  Law360 (subscription)
Related articles »  
Savient Pharma Unveils Ch. 11 Plan
Law360, New York (February 10, 2014, 7:01 PM ET) -- Drug developer Savient Pharmaceuticals Inc. unveiled its Chapter 11 plans in Delaware bankruptcy court Monday, calling for the liquidation of its U.S.
Related articles »  
Savient Pharma: Still Struggling To Grow KRYSTEXXA Sales
After reporting Q3 earnings, Savient Pharma (SVNT) plummeted back to a $1 from the meteoric rise to nearly $3 during the quarter.
Savient Pharmaceuticals: Value Play Or Value Trap?
Savient Pharmaceuticals, Inc. (SVNT), based in East Brunswick, NJ is a biotechnology company engaged in the commercialization of Krystexxa (first and only in its class), for refractory chronic gout (RCG), an indication for which SVNT has obtained ...
DEADLINE ALERT: Rigrodsky & Long, PA Reminds Shareholders Of Savient ...
Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of Savient Pharmaceuticals, Inc. (“Savient” or the “Company”) (OTC QB: SVNTQ) of an upcoming deadline involving a securities ...
Related articles »  
Trying to Get a Handle on Savient Pharmaceuticals' Valuation
It is the same company that was selling for $22/share a few days ago. There have been no accounting irregularities. No new problems with the drug have been discovered.
Savient Pharma: The Pharma Rising From The Dead
Over the last year, Savient Pharma (SVNT) has undergone a disappointing sales launch of a promising drug, the hiring and defection to Dendreon (NASDAQ:DNDN) of a big name CEO, and finally the lawsuit of a creditor for forced liquidation.